Please assess the completion status of the following clinical trial:

Trial Title: Trial to Evaluate the Efficacy and Safety of Dapagliflozin in Japanese Type 2 Diabetes Mellitus Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~* Japanese Subjects with type 2 diabetes mellitus.~* Strictly/relatively treatment naïve Subjects with HbA1c ≥ 7.0% and ≤ 10%, or Subjects treated with single or two (less than half of the approved maximal dose for each) oral anti-hyperglycaemic agent with HbA1c ≤ 8%.~* Provision of informed consent.~Exclusion Criteria:~* Having clinically relevant medical history or concurrent disease such as cardiovascular disease, renal disease, retinopathy, hepatic disease and haematological disease.~* The investigator(s) judged that the Subject should not participate in the study according to screening test or medical history.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 79 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): 1mg dapagliflozin
- 2 (Type: EXPERIMENTAL): 2.5mg dapagliflozin
- 3 (Type: EXPERIMENTAL): 5mg dapagliflozin
- 4 (Type: EXPERIMENTAL): 10mg dapagliflozin
- 5 (Type: PLACEBO_COMPARATOR): Placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).